The potential benefits of ACEi against COVID-19 are likely specific to hypertensive patients and purported to result from increasing lung membrane ACE2 expression during the second phase of SARS-CoV-2 infection (Huang et al., 2020). This evidence concerns the gene ACE2 and COVID-19.